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Peripheral T-cell lymphomas not otherwise specified are generally considered aggressive non-Hodgkin lymphomas,
because of poor natural outcome and response to therapy. They show a complex karyotype without any specific
genetic hallmark. We report a case of peripheral T-cell lymphoma not otherwise specified with heterogeneous
nuclear Cyclin D1 immunohistochemical overexpression, due to gene copy gain, a phenomenon similar to that
observed in Mantle Cell Lymphoma characterized by t(11;14)(q13;q32). In this case report we underline the
diagnostic pitfall rapresented by Cyclin D1 immunoistochemical overexpression in a T-cell lymphoma. Several
pitfalls could lead to misinterpretation of diagnosis, therefore, we underlined the need to integrate the classical
histology and immunohistochemistry with molecular tests as clonality or Fluorescence in situ hybridization.
Virtual slide: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1117747619703769
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Peripheral T-cell lymphomas (PTCLs) represent an het-
erogeneous group of non-Hodgkin's lymphomas (NHL),
characterized by poor outcome, accounting approxi-
mately for 10%-15% of all non-Hodgkin lymphomas in
the western countries, and with an higher prevalence in
Asia [1,2]. Peripheral T-cell lymphomas derive from
lymphocytes at the post-thymic stage of maturation.
According to recent WHO (World Health Organization)
classification more than 20 biologically and clinically dis-
tinct entities of Peripheral T-cell lymphomas have been
described, such as Peripheral T-cell lymphomas Not
Otherwise Specified (NOS), angioimmunoblastic T-cell
lymphoma (AITL), natural killer/T-cell lymphoma, adult
T-cell leukemia/lymphoma (ATLL) and anaplastic large-
cell lymphoma (ALCL), the most common ones [3]. Cu-
taneous lymphomas represent a distinct entity of T
lymphomas according to WHO, because same of those
show even an indolent course [4]. Unlike other non-
Hodgkin's lymphomas, only two subtypes of Peripheral* Correspondence: r.franco@istitutotumori.na.it
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reproduction in any medium, provided the orT-cell lymphomas are characterized by disease-defining
genetic abnormalities, such as the t(2;5)(p23;q35) in ana-
plastic large-cell lymphoma and DNA integration of
human T-lymphotropic virus 1 (HTLV1) in adult T-cell
leukemia/lymphoma [5,6]. Peripheral T-cell lymphomas-
Not Otherwise Specified account approximatively for
60-70% of T-cell lymphomas and it cannot be furtherly
classified on the basis of morphology, phenotype, and
conventional molecular studies, representing often a
diagnosis of exclusion with respect to other T cell
lymphomas histotypes [7].
Cyclin D1 is well-established human oncogene, fre-
quently deregulated in cancer, playing a specific role in
cancer phenotype characterization and disease progres-
sion [8]. Cyclin D1 over-expression is often due to
chromosomal aberration. Among lymphomas, transloca-
tion (11;14)(q13;q32) is typically observed in mantle cell
lymphoma. Thus the cyclin D1 gene at chromosome
11q13 is juxtaposed to IgH gene on chromosome 14q32,
resulting in overexpression of cyclin D1 [9,10].
Moreover cyclin D1 amplification and gain copies with
consequent protein over-expression have been fre-
quently described in multiple myeloma, T cutaneous
lymphomas and in solid cancer, such as oral squamousLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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[11,12]. Cyclin D1 gene abnormality has also described
in cutaneous lymphoma where the cyclin D1 gene copy
gain is an infrequent event and it seems associated to
malignant phenotype [12].
Here we report a case of Peripheral T-cell lymphomas
Not Otherwise Specified with cyclin D1 gene copy gain
associated with protein overexpression.
Case presentation
A 74 year old man was admitted to Hematology Unit of
Moscati Hospital, Avellino, because of multiple superfi-
cial adenopathies, splenomegaly and bilateral lower
limbs lymphedema. Laboratory data revealed elevated
LDH levels, hyperuricemia and positivity for hepatitis B
antibodies. Peripheral blood counts were normal, since
leucocitosi was not found. Parametres are as follows:
white blood cells count (WBC) 8500/mmc (Neutrophilis
73.5%; Leukocytes 20.8% Monocytes 5,5%); red blood
cells count (RBC) 3.970000/mmc Haemoglobin (Hb)
13,4 g/dl; hematocrit (HCT) 38.3%; mean corpuscular
volume (MCV) 96,4 Platelet count (PLT) 129.000/mmc.
On the basis of this clinical presentation and histo-
logical findings was excluded a diagnosis of lymphoma
with a leukemic presentation. CT (computed tomog-
raphy) scan showed multiple deep and superficial
lymph-nodes enlargement in the neck, thorax and abdo-
men. Focal hypoechoic lesions were detectable in the
spleen. A latero-cervical/submandibular nodal biopsy
was performed for diagnosis purpose. The specimen was
fixed in 10% neutral buffered formalin and paraffin em-
bedded. Five microns thick sections were stained with
hematoxylin and eosin for histological examination
(Figure 1).
Further sections were utilized for immunohistochem-
ical study, performed with Ventana automatic stainer .
Antibodies against CD2, CD3, CD4, CD8, CD5, CD43,
bcl2, bcl6, CD10, CD56, CD57, CD1a, CD34, CD99,
CD30, ALK1, CD23, CD20, CD79a, BSAP/Pax5, MIB1
and cyclin D1 were tested.
The histological examination showed an effacement of
the normal lymphoid parenchyma, because of the diffuse
relatively monotonous proliferation of atypical, small-
medium size cells with rounded or irregularly cleaved
nuclei, finely dispersed chromatin and inconspicuous
nucleoli. The proliferation showed a predominantly
paracortical pattern of growth, entrapping residual folli-
cles. Occasional larger cells were interspersed. The mi-
totic activity was high.
Neoplastic cells show immunohistochemical positivity
for T cell markers (CD2, CD3, CD5, CD43, CD4) and
bcl2 (Figure 1); B cell markers (CD20, CD79a and
BSAP/Pax5) were expressed in residual follicles, in
which a CD23 positive dendritc cells meshwork wasoccasionally observed (Figure 1). The atypical cells were
unreactive to CD10, CD8, CD56, CD57, CD1a, CD34,
CD99 and ALK1. Only rare larger cells stained with
CD30. The proliferation marker MIB1 was positive in al-
most 80% of cells. Unexpectedly cyclin D1 antibody was
expressed by a cospicous part of the neoplastic T cells
(Figure 2).
A peripheral T cell lymphoma, unspecified, was diag-
nosed, according to the morphology and immunopheno-
type, with unusual cyclin D1 expression.
Moreover molecular analysis of IgH and TCR re-
arrangement was done. In particular detection of B
clonality was investigated by identification of VDJ seg-
ments amplification of the hypervariable region of im-
munoglobulin heavy chain (IgH) using multiple primers
complementary to conserved regions in the involved
gene (Nanogen-Master Diagnòstica); the detection of T
clonality was investigated by identification of VJ seg-
ments amplification of TCRgamma gene using primers
complementary flanking regions of the V and the J seg-
ments (Nanogen-Master Diagnòstica). In electrophoresis
study, clonal rearrangement of TCR gamma gene is
shown by the presence of a single strong sharp band
within the expected size range from clonal control ( Fig-
ure 3). Our PCR analysis definitively demonstrated neo-
plastic T cell proliferation, being clonally rearranged for
TCRgamma gene, in particular our sample presents VJ-B
rearrangement as shown from band approximately for
215bp (Figure 3).
Although morphological and immunoprofile excluded
a mantle cell lymphoma, chromosomal translocation
(11; 14) (q13; q32) involving cyclin D1/IGH genes has
been searched. FISH analysis for the detection of cyclin
D1 status was performed using Vysis LSI IGH/CCND1
XT Dual Color Dual Fusion Probes (Vyses). This probe
set uses the dual-color, dual fusion strategy and consists
of a mixture of locus-specific fluorophore-labelled DNA
probes containing sequences homologous to the IGH
regions (Spectrum Green) and cyclin D1 breakpoint
region (Spectrum Orange). The cyclin D1 contig is
composed of three segments covering a region approxi-
mately of 942Kb locus 11q13 where are present differ-
ent genes including cyclin D1. Green fluorescent spots
represent Igh and red spots stand for cyclin D1. In a
normal tissue we have two split signals of both colors
while in a traslocated sample we have two or one fused
signals (yellow). The cytogenetic analyses revealed a
copy gain of the cyclin D1 without evidence of trans-
location because the sample shows two split signals of
both colours (Figure 3). Bone marrow biopsy showed a
huge CD3+ T cell lymphoma infiltration (Figure 4).
The patient was placed on GEMOX chemotherapy
regimen (gemcitabine and oxalyplatin). Only one cycle
of therapy was administered because of hematological
Figure 1 Photomicrographs of Peripheral T cell lymphoma morphology and immunostaining. (A) and (B) hematoxylin and eosin
morphology 20X and 100X magnification respectively. C) CD 20 immunostaining (40X magnification). D) strong CD3 positivity (20X
magnification). E) CD5 immunostaining positivity (40X magnification). F) CD43 expression (40X magnification).
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months after the diagnosis.
In this short report we show overexpression of cyclin
D1 in a peripheral T-cell lymphoma.
Worldwide, Peripheral T-cell lymphomas represent ap-
proximately 12% of all non-Hodgkin's lymphomas [13].
Although Peripheral T-cell lymphomas Not Otherwise
Specified represent most of the T-cell lymphomas, the
genetic features are only poorly characterized [14]. Gene
profiling studies performed on small series of Peripheral
T-cell lymphomas showed frequent aberrations, particu-
larly over-expression of critical genes involved in a pro-
liferation signature, also significantly associated with
shorter survival. This proliferation signature included
genes commonly involved in cell cycle progression, such
as CCNA, CCNB, TOP2A, and PCNA [15].
Cyclins play a central role in cell cycle regulation and
are involved in the pathogenesis of specific hematologic
malignancies. D-cyclins (D1, D2, and D3) are structurally
and functionally similar proteins that bind and activate
cyclin-dependent kinases 4 and 6 during the G1 phase
of the cell cycle as the cell prepares to initiate DNAsynthesis [16]. In mammalian cells, deregulation of these
proteins leads to significantly increased cell proliferation
and turnover [17].
In the current literature, T-cell lymphoma subtypes
could be characterized by overexpression of cyclin D2,
D3, in particular when proliferation rate is greater than
50% [8]. In addition increased Cyclin D1 expression has
been observed in 9 of 23 Mycosis Fungoides (39%), 7 of
10 C- primary cutaneous CD30+ anaplastic large-cell
lymphoma (70%), and 6 of 30 Sezary Syndrome (20%)
[12]. On the contrary cyclin D1 overexpression, to the
best of our knowledge, has not been hitherto described
in nodal Peripheral T-cell lymphomas, Not Otherwise
Specified [17].
Cyclin D1 overexpression is described as a driving
molecular event in various types of cancer, including
mantle cell lymphoma (MCL), plasmacellular dyscrasia,
a subset of cutaneous T cell lymphomas, ,non-small
cell lung cancer, and carcinomas of breast, head and
neck, and esophagus [12,18-22]. In various studies,
cyclin D1 immunohistochemical expression in several
tumors seems to be related to other proliferation
Figure 2 Illustration of Peripheral T cell lymphoma immunostaining. (A) Bcl6 immunonegativity 60X magnification. B) MIB1 strong nuclear
immunopositivity in neoplastic T cells (40X). C) Cyclin D1 overexpression in neoplastic T cells (60X).
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regulatory proteins such as CDK4, p21, E2F1 proapop-
totic protein p53, and inversely correlated with expres-
sion of tumor suppressor pRb protein, and bcl-2 [23-
26]. In the literature, there are conflicting reports
about prognostic impact of cyclin D1 expression and
clinical outcome of different cancers. Cyclin D1 over-
expression is responsible for the cell cycle deregulation
playing a significant role for a greater aggressiveness,
tumour extension, regional lymph node metastases and
advanced clinical stage in many cancer types, such as
oral cancer, breast cancer and lung cancer [27-29].
Cyclin D1 may be a prognostic indicator for survival
[30,31]. Many studies confirm that cyclin D1 over ex-
pression is indicative of poor outcome in B cell lymph-
oma patients and as it might be used also as poor
prognostic index as in our case [32].Aberrant expression of Cyclin D1 can be due to
chromosomal translocations, single nucleotide poly-
morphism and gene amplification or copy gains.
Chromosomal translocation is a common genetic mech-
anism for the pathogenesis of B-cell lymphomas [18]. In-
deed more than 90% of mantle cell lymphoma is
characterized by t(11; 14) (q13; q32) [9]. In addition
translocation involving Cyclin D1, i.e. t(11; 14) (q23;
q32), is also observed in 15-25% of non-IgM MGUS
(monoclonal gammopathy of undetermined significance)
[33]. As a consequence of this translocation, cyclin D1 is
constitutively expressed under the control of an active Ig
locus in B cells presenting traslocation. Elevated expres-
sion of cyclin D1 has also been demonstrated in other
lymphoproliferative disorders as hairy cell leukemia,
plasma cell dyscrasias, rare cases of B-cell chronic
lymphocytic leukemia/ small lymphocytic lymphoma
Figure 3 FISH analysis using a IGH/ CCND1 t(11;14) probe and Clonality results in 2% agarose gel (A) and (B) Green fluorescent spots
represent Igh and red spots stand for CCND1. Both pictures show distinct red and green signals (split signals indicating no translocation) and
an increase red signals (cyclin D1 copy gain) at different magnification 63x and 100x respectively. C) Analysis of results of B Clonality in 2%
agarose gel 1) FR1-JH monoclonal B control. 2) Sample. 3) FR1-JH polyclonal B control. 4) FR2-JH monoclonal B control. 5) sample. 6) FR2-JH
polyclonal B control. 7) FR3-JH monoclonal B control. 8) sample. 9) FR3-JH polyclonal B control. D) Analysis of results of T Clonality in 2% agarose
gel 1)VJ-A monoclonal T control. 2) sample. 3) VJ-A polyclonal control. 4)VJ-B monoclonal T control. 5) sample. 6) VJ-B polyclonal control. 7) Beta-
Actin Control.
Figure 4 Peripheral T- cell Lymphoma infiltration, bone marrow biopsy: A) hematoxylin and eosin morphology 20X magnification; B)
CD 3 Immunopositivity shows infiltration by neoplastic T cells 20X magnification.
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locus 11q13 cyclin D1 has been described in melanomas
and it is strictly related to prognosis. [34] Gene amplifi-
cations of cyclin D1 with consequent overexpression has
been reported in several tumor types such as head and
neck cancer, pituitary tumors, esophageal squamous cell
carcinoma, and breast cancer. [20,35-37] In addition,
also small genetic changes such as single nucleotide
polymorphisms, producing specific cyclin D1 splice vari-
ant, have been described as responsible of cyclin D1
overexpression [38]. Further cyclin D1 G/A870 poly-
morphism has been implicated as a modulator of cancer
risk and/or poor prognosis in human disease. [39]Conclusion
In this paper we described a case of peripheral T cell
lymphoma with atypical expression of cyclin D1. The
monomorphic Cyclin D1 high proliferation observed in
this case led to a diagnosis with other lymphomas, in
particular with mantle cell lymphoma. In addition, we
showed molecular alteration never described in the lit-
erature for this type of lymphoma which affects cyclin
D1 expression through gene gain of function. This ab-
normality produces a dysregulation of the cell cycle and
it could have contribute to a more aggressive behavior of
this lymphoma. Since we consider the difficult that the
pathologists encounter in the diagnosis of T cell lymph-
omas and we underline the importance of molecular
biology integration tests as a diagnostic tool to escape
the pitfall.Consent
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